Cyclica

The Toronto-based biotechnology startup Cyclica uses biophysics and artificial intelligence (AI) to accelerate, secure, and reduce the cost of medication discovery. By providing an integrated network of technology to all scientists in the pharmaceutical industry, they allow drug discovery and revolutionize a system plagued by attrition and expensive failures. Cyclica is one of the largest biotech companies in Canada

In order to provide light on target discovery, drug action mechanisms, lead prioritization, and drug repurposing, their cloud-based Ligand Express platform de novo reveals the polypharmacological profiles of small compounds. By examining the effects of genetic variations on protein structure, they have increased the utility of Ligand Express downstream and gained an understanding of structural pharmacogenomics.

The complexity of the disease is embraced by Cyclica from molecule to treatment. With strong industry ties, a cutting-edge platform, and a ground-breaking decentralized collaboration approach, Cyclica is more precisely developing medications to meet unmet patient needs. Their work includes numerous joint ventures and numerous collaborations with major pharma and biotech companies. Cyclica is a committed group of biotech and pharmaceutical industry experts, biologists, chemists, and computer scientists who work at the nexus of their respective fields of specialization.

Founded: 2010

Headquarters: Toronto, Canada

Website: https://cyclicarx.com/about/